← Back to Search

Senolytic Therapy

Dasatinib + Quercetin for Alzheimer's Disease (SToMP-AD Trial)

Phase 1 & 2
Waitlist Available
Led By Nicolas Musi, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from 0 to 12 weeks
Awards & highlights

SToMP-AD Trial Summary

This trial is testing whether a combination of two drugs can penetrate the brain to treat Alzheimer's symptoms.

SToMP-AD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from 0 to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from 0 to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brain Penetrance of Dasatinib (D)
Brain Penetrance of Quercetin (Q)
Secondary outcome measures
Alzheimer's Disease Marker - CSF Amyloid Beta
Alzheimer's Disease Marker - CSF Tau
Electronic Gait Mapping Under Single and Dual-task Conditions
+3 more

Side effects data

From 2023 Phase 1 & 2 trial • 5 Patients • NCT04063124
40%
Urinary tract infection
20%
Hematuria
20%
Emesis
20%
Hypoglycemia
20%
Fall
20%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intermittent D+Q

SToMP-AD Trial Design

1Treatment groups
Experimental Treatment
Group I: Intermittent D+QExperimental Treatment1 Intervention
Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dasatinib + Quercetin
2016
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
452 Previous Clinical Trials
91,409 Total Patients Enrolled
Mayo ClinicOTHER
3,206 Previous Clinical Trials
3,767,078 Total Patients Enrolled
Nicolas Musi, MDPrincipal InvestigatorUT Health San Antonio
5 Previous Clinical Trials
241 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
How old are they?
65+
What site did they apply to?
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Mechanisms of Ageing and DevelopmentJournal
A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials
Gonzales, Mitzi M., Sudarshan Krishnamurthy, Valentina Garbarino, Ali S. Daeihagh, Gregory J. Gillispie, Gagan Deep, Suzanne Craft, and Miranda E. Orr. 2021. “A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials”. Mechanisms of Ageing and Development. Elsevier BV. doi:10.1016/j.mad.2021.111589.
Mechanisms of Ageing and DevelopmentJournal
A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials
Gonzales, Mitzi M., Sudarshan Krishnamurthy, Valentina Garbarino, Ali S. Daeihagh, Gregory J. Gillispie, Gagan Deep, Suzanne Craft, and Miranda E. Orr. 2021. “A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials”. Mechanisms of Ageing and Development. Elsevier BV. doi:10.1016/j.mad.2021.111589.
Mechanisms of Ageing and DevelopmentJournal
A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials
Gonzales, Mitzi M., Sudarshan Krishnamurthy, Valentina Garbarino, Ali S. Daeihagh, Gregory J. Gillispie, Gagan Deep, Suzanne Craft, and Miranda E. Orr. 2021. “A Geroscience Motivated Approach to Treat Alzheimer’s Disease: Senolytics Move to Clinical Trials”. Mechanisms of Ageing and Development. Elsevier BV. doi:10.1016/j.mad.2021.111589.
The Journal of Prevention of Alzheimer's DiseaseJournal
Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (stomp-ad): A Pilot Clinical Trial
Gonzales, M.M., V.R. Garbarino, E. Marques Zilli, R.C. Petersen, J.L. Kirkland, T. Tchkonia, N. Musi, S. Seshadri, S. Craft, and M.E. Orr. 2021. “Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (stomp-ad): A Pilot Clinical Trial”. The Journal of Prevention of Alzheimer's Disease. SERDI. doi:10.14283/jpad.2021.62.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top